IDO1 and non-small cell lung carcinoma: In a phase-1 trial to evaluate the efficacy and safety of IDO vaccines in advanced non-small-cell lung cancer (NCT01219348), a favorable median overall survival was observed, with no grade-3 or -4 toxicities.